Christopher Raymond
Stock Analyst at Raymond James
(2.67)
# 1,855
Out of 5,182 analysts
142
Total ratings
50.43%
Success rate
1.12%
Average return
Main Sectors:
Stocks Rated by Christopher Raymond
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ALMS Alumis | Initiates: Strong Buy | $46 | $23.37 | +96.83% | 1 | Mar 11, 2026 | |
| CLYM Climb Bio | Initiates: Strong Buy | $25 | $6.56 | +281.10% | 1 | Mar 11, 2026 | |
| COGT Cogent Biosciences | Maintains: Overweight | $39 → $52 | $35.21 | +47.69% | 2 | Feb 18, 2026 | |
| ARDX Ardelyx | Upgrades: Overweight | $10 → $16 | $5.94 | +169.36% | 11 | Jan 9, 2026 | |
| LXEO Lexeo Therapeutics | Initiates: Strong Buy | $25 | $5.72 | +337.06% | 1 | Dec 18, 2025 | |
| TSHA Taysha Gene Therapies | Initiates: Strong Buy | $13 | $4.37 | +197.48% | 3 | Oct 21, 2025 | |
| MGTX MeiraGTx Holdings | Initiates: Strong Buy | $29 | $9.18 | +215.90% | 2 | Oct 21, 2025 | |
| ABVX ABIVAX Société Anonyme | Maintains: Overweight | $42 → $70 | $118.37 | -40.86% | 2 | Jul 23, 2025 | |
| BIIB Biogen | Maintains: Neutral | $135 → $115 | $177.34 | -35.15% | 21 | Apr 29, 2025 | |
| ALXO ALX Oncology Holdings | Maintains: Overweight | $8 → $9 | $1.97 | +356.85% | 6 | Mar 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $122 → $126 | $55.50 | +127.03% | 15 | Feb 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $20 → $4 | $6.38 | -37.30% | 3 | Feb 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $220 → $227 | $208.84 | +8.70% | 12 | Jan 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $535 → $533 | $438.71 | +21.49% | 8 | Jan 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $1,195 → $1,013 | $761.85 | +32.97% | 7 | Jan 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $135 → $140 | $22.45 | +523.61% | 5 | Jan 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $72 | $55.13 | +30.60% | 1 | Jan 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $3 → $13 | $4.20 | +209.52% | 2 | Nov 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $60 → $75 | $5.89 | +1,173.34% | 4 | Nov 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $66 → $76 | $9.80 | +675.51% | 7 | Sep 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $10 | $0.03 | +30,859.75% | 2 | Sep 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $33 | $39.61 | -16.69% | 1 | Aug 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $2 → $4 | $1.38 | +189.86% | 3 | May 31, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $293 → $288 | $347.94 | -17.23% | 16 | Apr 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $41 | $35.20 | +16.48% | 1 | Feb 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $28 | $33.03 | -15.23% | 1 | Jul 26, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $40 | $105.43 | -62.06% | 1 | Aug 23, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $90 | $7.49 | +1,101.60% | 1 | Jul 12, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $96 | $1.13 | +8,395.58% | 2 | Mar 13, 2020 |
Alumis
Mar 11, 2026
Initiates: Strong Buy
Price Target: $46
Current: $23.37
Upside: +96.83%
Climb Bio
Mar 11, 2026
Initiates: Strong Buy
Price Target: $25
Current: $6.56
Upside: +281.10%
Cogent Biosciences
Feb 18, 2026
Maintains: Overweight
Price Target: $39 → $52
Current: $35.21
Upside: +47.69%
Ardelyx
Jan 9, 2026
Upgrades: Overweight
Price Target: $10 → $16
Current: $5.94
Upside: +169.36%
Lexeo Therapeutics
Dec 18, 2025
Initiates: Strong Buy
Price Target: $25
Current: $5.72
Upside: +337.06%
Taysha Gene Therapies
Oct 21, 2025
Initiates: Strong Buy
Price Target: $13
Current: $4.37
Upside: +197.48%
MeiraGTx Holdings
Oct 21, 2025
Initiates: Strong Buy
Price Target: $29
Current: $9.18
Upside: +215.90%
ABIVAX Société Anonyme
Jul 23, 2025
Maintains: Overweight
Price Target: $42 → $70
Current: $118.37
Upside: -40.86%
Biogen
Apr 29, 2025
Maintains: Neutral
Price Target: $135 → $115
Current: $177.34
Upside: -35.15%
ALX Oncology Holdings
Mar 6, 2025
Maintains: Overweight
Price Target: $8 → $9
Current: $1.97
Upside: +356.85%
Feb 20, 2025
Maintains: Overweight
Price Target: $122 → $126
Current: $55.50
Upside: +127.03%
Feb 11, 2025
Downgrades: Neutral
Price Target: $20 → $4
Current: $6.38
Upside: -37.30%
Jan 27, 2025
Maintains: Overweight
Price Target: $220 → $227
Current: $208.84
Upside: +8.70%
Jan 27, 2025
Maintains: Overweight
Price Target: $535 → $533
Current: $438.71
Upside: +21.49%
Jan 27, 2025
Maintains: Overweight
Price Target: $1,195 → $1,013
Current: $761.85
Upside: +32.97%
Jan 13, 2025
Maintains: Overweight
Price Target: $135 → $140
Current: $22.45
Upside: +523.61%
Jan 10, 2025
Initiates: Overweight
Price Target: $72
Current: $55.13
Upside: +30.60%
Nov 18, 2024
Upgrades: Overweight
Price Target: $3 → $13
Current: $4.20
Upside: +209.52%
Nov 6, 2024
Maintains: Overweight
Price Target: $60 → $75
Current: $5.89
Upside: +1,173.34%
Sep 23, 2024
Maintains: Overweight
Price Target: $66 → $76
Current: $9.80
Upside: +675.51%
Sep 3, 2024
Maintains: Overweight
Price Target: $10
Current: $0.03
Upside: +30,859.75%
Aug 15, 2024
Initiates: Overweight
Price Target: $33
Current: $39.61
Upside: -16.69%
May 31, 2023
Upgrades: Overweight
Price Target: $2 → $4
Current: $1.38
Upside: +189.86%
Apr 28, 2023
Maintains: Overweight
Price Target: $293 → $288
Current: $347.94
Upside: -17.23%
Feb 3, 2023
Initiates: Overweight
Price Target: $41
Current: $35.20
Upside: +16.48%
Jul 26, 2022
Initiates: Overweight
Price Target: $28
Current: $33.03
Upside: -15.23%
Aug 23, 2021
Initiates: Overweight
Price Target: $40
Current: $105.43
Upside: -62.06%
Jul 12, 2021
Initiates: Neutral
Price Target: $90
Current: $7.49
Upside: +1,101.60%
Mar 13, 2020
Downgrades: Neutral
Price Target: $96
Current: $1.13
Upside: +8,395.58%